We have investigated whether central inhibi tion of nitric oxide synthase (NOS) could modify the tis sue damage of focal cerebral ischemia produced by occlusion of the middle cerebral artery (MCA) in rats. �-Nitro-L-arginine methyl ester (L-NAME) was admin istered intracerebroventricularly at two doses 15 min prior to occlusion of the MCA, as well as 4 and 24 h following occlusion. After the injection of L-NAME, the catalytic activity of the constitutive NOS, considered to be mainly neuronal, was effectively suppressed in the sub cortical gray matter bilaterally, but not in the ischemic territory. Seven days after the MCA occlusion, the brains were evaluated for histopathologic damage. High-dose
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We have investigated whether central inhibi tion of nitric oxide synthase (NOS) could modify the tis sue damage of focal cerebral ischemia produced by occlusion of the middle cerebral artery (MCA) in rats. �-Nitro-L-arginine methyl ester (L-NAME) was admin istered intracerebroventricularly at two doses 15 min prior to occlusion of the MCA, as well as 4 and 24 h following occlusion. After the injection of L-NAME, the catalytic activity of the constitutive NOS, considered to be mainly neuronal, was effectively suppressed in the sub cortical gray matter bilaterally, but not in the ischemic territory. Seven days after the MCA occlusion, the brains were evaluated for histopathologic damage. High-dose Nitric oxide (NO) has been described as an im portant, short-lived molecule with a variety of bio logical actions (Moncada et ai., 1991; Bredt and Snyder, 1992; Dawson et ai., 1992b; Dawson and Snyder, 1994) . NO is synthesized from L-arginine by NO synthase (NOS) (Moncada et ai., 1989) . At least four sources of NO influence the central ner vous system. The nitric oxide originating from the endothelium is a vasodilator and is thought to be the endothelium-derived relaxing factor (EDRF) (Palmer et ai., 1987) . NO is also produced in cere bral perivascular nerve fibers, which are responsi ble for nonadrenergic noncholinergic vasodilatation administration of L-NAME (120 f1g/kg 15 min prior to MeA occlusion, followed by 150 f1g/kg 4 and 24 h after occlusion) produced an enlargement of the infarct area and increased the volume of ischemic damage. These re sults indicate that extensive inhibition of NOS by a cen tral route can increase the cerebral infarct size in focal ischemia even if NOS is not inhibited in the ischemic tissue and suggest that NO may also play a potentially beneficial role as well as a neurode , structive role in the pathophysiological mechanisms of focal cerebral isch emia. Key Words: Cerebral ischemia-Middle cerebral ar tery occlusion-Nitric oxide-Nitric oxide synthase �-nitro-L-arginine methyl ester-Rat. (Toda and Okamura, 1990; Nozaki et ai., 1993) . The third source of NO is neurons and glia, which con tain NOS that may be partly responsible for the coupling between cerebral blood flow and metabo lism (ladecola, 1993) , for modifying synaptic effi cacy, and for facilitating the release of neurotrans mitters (Gally et ai., 1990) . A constitutive NOS, which is regulated by a calcium/calmodulin dependent mechanism, is responsible for these first three sources of NO. NO is also produced by an inducible non-calcium-dependent type of NOS in macrophages, microglia, astrocytes, and endotheli al cells in a variety of pathologic states (F6rster mann et ai., 1991) .
NO has become established as a diffusible mes senger mediating cell-to-cell interactions in the brain including the cell-mediated immune system, cerebral smooth muscle relaxation, and inhibition of platelet aggregation (Moncada et ai., 1988 (Moncada et ai., , 1991 . In addition, NO is a diffusible neuronal transmitter with characteristics that differentiate it from the classic neurotransmitters (Bredt and Snyder, 1992) and with a role in the modulation of synaptic plas ticity and learning (Zorumski and Izumi, 1993) .
A role for NO in the pathogenesis of brain dam age in cerebral ischemia and hypoxia has also been postulated. It has recently been shown in vitro that NO is involved in the N-methyl-D-aspartate (NMDA) receptor-mediated neurotoxicity of the excitatory amino acid glutamate (Dawson et ai., 1991 (Dawson et ai., , 1993 Dawson and Snyder, 1994 ), suggesting that NO may induce the neurotoxicity produced by excitatory amino acids in cerebral ischemia (Mel drum and Garthwaite, 1990) . There are some re ports that inhibition of NOS reduces the infarct vol ume produced by focal ischemia in the mouse (Nowicki et ai., 1991) , rat (Buisson et ai., 1992) , and cat (Nishikawa et ai., 1993) . In contrast, NO pro duction in cerebral vascular muscle cells and endo thelial cells may be neuroprotective in cerebral ischemia by increasing blood flow to the ischemic brain tissue (Morikawa et ai., 1992b (Morikawa et ai., , 1994 . Ya mamoto et ai. (1992) found that treatment with the NOS inhibitor, N-w-nitro-L-arginine (NNA), in creased the infarct volume in spontaneous hyper tensive rats in which the middle cerebral artery (MCA) had been occluded, and Morikawa et ai. (l992a) reported that L-arginine, a precursor of NO, reduced the size of damaged tissues in a similar focal ischemia modei. These in vivo studies indicate that the role of NO in cerebral ischemia is still un clear.
In spite of many in vivo studies using inhibitors of NOS by intraperitoneal or intravenous routes (sys temic administration), there have been no investi gations on the effect of intracerebroventricular (i.c. v.) injection of NOS inhibitors in focal isch emia. This route of administration directly inhibits NOS centrally without changes in blood pressure (Moore et ai., 1991) . The purpose of the present study was (a) to examine the effect of i.c. v. admin istration of the NOS inhibitor, �-nitro-L-arginine methyl ester (L-NAME), on the catalytic activity of constitutive NOS and (b) to evaluate the effect of i.c.v. administration of L-NAME on cerebral isch emic damage produced by occlusion of the MCA.
MATERIALS AND METHODS

Animal preparation
Sixty-seven adult male Wistar rats (weight, 250-350 g) were used in this study. Before surgery, animals were fasted overnight with free access to tap water. For place ment of the intracerebroventricular cannula, animals were anesthetized with an intraperitoneal injection of pentobarbital sodium, 35 mg/kg, and positioned in a ste reotaxic frame. Atropine sulfate, 0.15 mg/kg, was injected intramuscularly to reduce respiratory secretions. A scalp incision was made over the sagittal suture, and a hole (diameter, 1.5 mm) was drilled in the left parietal bone to J Cereb Blood Flow Metab, Vol. 15, No.5, 1995 expose the dural surface at coordinates 1.0 mm lateral and 1.0 mm posterior to the bregma. A 22-G, sterile stain less-steel cannula (C313; Plastics One Inc., Roanoke, VA, U.S.A.) was lowered 4.0 mm ventral from the dural surface into the left lateral ventricle with a micromanip ulator. U sing three small screws placed in the skull as anchors, the cannula was fixed to the skull with dental acrylic. A sterile 27-G obturator with a plastic screw fit ting was inserted into the cannula to maintain patency. To prevent infection, 0.5 mg gentamicin hydrochloride was topically applied to the wound, and after suturing, the animal was returned to the cage. The duration of this surgical preparation was -25 min. The animals were placed in individual cages with food and water ad libitum for at least 72 h of recovery.
Prior to the surgical procedure for the occlusion of the MCA, the animals were fasted overnight with free access to tap water. They were anesthetized with halothane (4% for induction, 1-1.5% for surgical preparation) in a mix ture of 70% nitrous oxide and 30% oxygen, using a closely fitting facial mask. The tail artery was exposed and cath eterized with polyethylene tubing (PE-50) to allow blood samples to be taken for blood gas analysis, plasma glu cose, and hematocrit. The catheter was connected to a transducer for the continuous monitoring of blood pres sure, which was recorded continuously on a polygraph (Model 7D; Grass Instruments, Quincy, MA, U.S.A.). Arterial pH, Pa02, and Paco2 were determined by a blood gas analyzer (ABL 30; Radiometer, Copenhagen, Den mark) and plasma glucose coricentration was measured with a glucose analyzer (Glucose Analyzer 2; Beckman Instruments, Inc., Brea, CA, U.S.A.). Body temperature was continuously recorded on the same polygraph and maintained at 37°C with a thermostatically controlled heating lamp connected to a rectal thermistor probe (73A; Yellow Springs Company, Yellow Springs, OH, U.S.A.).
Focal cerebral ischemia was produced by bilateral common carotid artery occlusion along with occlusion of the distal portion of the right MCA by a modification of the method of Coyle (1982) , Chen et al. (1986) , and Brint et al. (1988) . Both common carotid arteries were carefully exposed through a ventral mid cervical incision and loops made from PE-IO polyethylene catheter were gently passed around the carotid arteries for later occlusion. A vertical incision was made between the right lateral can thus and the external auditory meatus, the temporal mus cle was retracted, and a burr hole was made in the un derlying parietal bone 2 to 3 mm rostral to the fusion of the zygomatic arch with the squamous bone using a den tal drill continuously cooled with a saline drip. The dura overlying the MCA was carefully cut and a fine stainless steel hook was placed under the MCA distal to its cross ing of the inferior cerebral vein with the aid of a micro manipulator. To prevent brain surface cooling, we oc cluded the MCA immediately after the exposure of the brain surface. Immediately after occluding both common carotid arteries, the MCA was lifted and cauterized with an electrocoagulator. The craniotomy was covered with a small piece of Gelfoam (Upjohn) and the wound was su tured to maintain the temperature of the brain surface. After 1 h of occlusion, the loop around the left common carotid artery was released and removed, permitting this vessel to reperfuse. The right common carotid artery, which had previously been occluded, was permanently ligated, the arterial catheter was removed, and all of the wounds were sutured. The anesthesia was discontinued and the animal was returned to its cage upon awakening. To prevent infection, antibiotics (3 mg gentamicin hydro chloride) were topically applied to the wounds and sterile procedures were used throughout.
Seven days later, the animals were reanesthetized with pentobarbital sodium and sacrificed by transcardiac per fusion fixation with 100 ml of phosphate-buffered saline, followed by 100 ml of a 10% paraformaldehyde solution. The brain was carefully removed from the skull and stored in 10% paraformaldehyde solution for at least I week. The position of the i.c. v. cannula in the lateral ventricle was confirmed in all animals. Coronal brain sec tions were obtained every 500 f.Lm and stained with he matoxylin and eosin. Each section was identified by ref erence to the corresponding level in an atlas of the rat brain (Paxinos and Watson, 1986) . The borders of the infarct area were marked microscopically by a neuro pathologist blinded to the drug treatment. The cross sectional infarct area was analyzed with a computerized image analysis system (Dumas, Drexel University, Phil adelphia, PA, U.S.A.) and the infarct volume was calcu lated from the cross-sectional area and distance between sections.
Measurement of NOS catalytic activity
Animals were anesthetized with 4% halothane in a mix ture of 70% nitrous oxide and 30% oxygen and sacrificed by decapitation. The brains were removed and dissected into four pieces-left and right cerebral cortex, fed by the MCA, and left and right deep gray matter, comprising mainly the striatum and the thalamus (Fig. l) . These pieces were immediately frozen in liquid nitrogen and stored at -80°C until analysis for NOS catalytic activity by the method of Snyder (1989, 1990) .
NOS catalytic activity study
Thirty-six rats divided into six groups were used for measurement of NOS catalytic activity. The animals were anesthetized with halothane in a mixture of nitrous oxide and oxygen. The NOS inhibitor L-NAME (Sigma, St. Louis, MO, U.S.A.) was dissolved in 3 f.Ll of saline ad justed to pH 7.4 with 0.1 M NaOH solution. The intra cerebroventricular infusion of the drug or the vehicle was made over 5 min using a 27-G tube attached to a 1O-1J..! Hamilton syringe and inserted through the indwelling cannula that had been previously placed into the left lat-eral ventricle. Group I (control group) was treated with the vehicle, 3 f.Ll of saline similarly pH adjusted. Group 2 was treated with 30 f.Lg/kg L-NAME, and groups 3 and 4 were injected with 120 and 240 f.Lg/kg, respectively. These four groups were sacrificed I h after administration of the drug. Groups 5 and 6 were sacrificed 4 h after i.c. v. in fusion and received the vehicle and 120 f.Lg/kg L-NAME, respectively.
Focal ischemia study
The effect of NOS inhibition on histological damage was studied in 31 rats. In one group, the animals were treated with 30 f.Lg/kg L-NAME in 3 f.Ll of saline. The L-NAME was administered intracerebroventricularly over 5 min starting 20 min prior to occlusion of the MCA. Four and twenty-four hours after occlusion of the MCA, the animals received i.c. v. 50 f.Lg/kg L-NAME in 5 f.Ll over 5 min (low-dose L-NAME). To facilitate treatment, the animals were briefly anesthetized with 1% halothane in nitrous oxide and oxygen during the i.c.v. drug adminis tration. A separate group of animals was treated with 120 f.Lg/kg L-NAME 15 min prior to MCA occlusion and with 150 f.Lg/kg L-NAME in 5 .. f.Ll at 4 and 24 h (high-dose L-NAME). A third group received the vehicle at the same times and in the same volumes as the low-and high-dose groups.
The experimental protocol was approved by the U ni versity Institutional Animal Care and Use Committee of the University of Pennsylvania.
Statistical analysis
Data were evaluated by analysis of variance (ANOY A) and Tukey's test for post hoc comparisons. Two-group comparisons were analyzed by Student's t test.
RESULTS
Physiological parameters of the focal ischemia study
All values of hematocrit, plasma glucose, Pao2, Paco2, and pH were within the physiological range. In addition, there were no significant differences in any of these parameters among the three groups (Table 1) . No significant changes occurred in mean arterial blood pressure (MABP) following i. c. v. Arterial blood samples were obtained I h after MCA occlusion. Values are expressed as means ± SD. The number of rats in each group is indicated in parentheses. There was no significant difference among any of the groups in any physiological parameter.
L-NAME infusions ( Table 2) . MABP increased sig nificantly after the MeA occlusion, with all three groups exhibiting comparable increases.
Effect of i.c.v. administration of L-NAME on NOS catalytic activity
In the left deep gray matter, NOS catalytic activ ity was 20 ± 17% of the control with 30 f.Lg/kg, 2 ± I % with 120 f.Lg/kg, and 2 ± 1 % with 240 f.Lg/kg, all significantly suppressed compared with the control (p < 0. 05) (Fig. 2) . In the right deep gray matter, NOS catalytic activity was 63 ± 24% of the control with 30 f.Lg/kg, 25 ± 12% with 120 f.Lg/kg, and 5 ± 2% with 240 f.Lg/kg. Both 120 and 240 f.Lg/kg L-NAME significantly suppressed NOS catalytic activity (p < 0. 05). In the left cerebral cortex 1 h after treatment, NOS catalytic activity was 57 ± 52% (mean ± SD) of the control following the administration of 30 f.Lg/ kg L-NAME, 33 ± 26% of the control following treatment with 120 f.Lg/kg L-NAME, and 47 ± 35% of the control with 240 f.Lg/kg L-NAME. Only with the 120 f.Lg/kg treatment was NOS catalytic activity significantly suppressed (p < 0. 05). In the right cor tex, catalytic activity was 63 ± 33% of the control with 30 f.Lg/kg L-NAME, 96 ± 41% with 120 f.Lg/kg, and 36 ± 14% with 240 f.Lg/kg. NOS catalytic activ ity was significantly lower than the control only in the animals treated with 240 f.Lg/kg L-NAME (p < 0. 05). The suppression of cortical NOS activity was variable and inconsistent, probably secondary to the bioavailability of L-NAME at sites distant from the cannula.
Four hours after i. c. v. administration of 120 f.Lgl kg L-NAME, the NOS catalytic activity was 9 ± 3% of the control in the left deep gray matter, 48 ± 14% in the right deep gray matter, 67 ± 46% in the left cortex, and 122 ± 43% in the right cortex. Only in the deep structures were these changes statistically significant with respect to the saline-injected ani mals (left, p < 0. 001; right, p < 0. 005).
Effects of inhibition of NOS on focal cerebral ischemia
Seven days of occlusion of the MeA resulted in a well-recognized infarct in the MeA territory of each animal. The lesion extended over 8 mm in a rostral caudal direction and included frontal, parietal, and occipital cortices primarily in the dorsal portion of the hemisphere, with the caudate and the putamen spared (Fig. 3 ). There was a clear uniformity in the distribution of the infarct which was similar in each group.
There was no significant difference in infarct area between the vehicle-treated and the low-dose group at any level. There was, however, a signifi cant difference in damage between the vehicle treated and the high-dose group (p < 0. 05; ANOYA). The sections 8. 2, 8. 7, and 10. 2 mm an terior to the interaural line from the high-dose group exhibited significantly more damage than corre sponding sections from the control group. In addi tion, the infarct area of the 8. 7-mm section from the high-dose group was significantly larger than that of the low-dose group. In several other sections, the infarct area of the high-dose group was larger than that of the control group, although these differences were not statistically significant (Fig. 3) .
For the purpose of calculating infarct volumes, the brain was divided into three sections along the rostrocaudal axis, each 2. 5 mm thick (Table 3 ). In the anterior section, the infarct volume of the high dose-treated group was significantly larger than that of both the control and the low-dose group (p < 0.05; ANOYA). In the middle and the posterior sec tions, as well as in the total brain, the infarct vol ume of the high-dose group was also larger than that of the control group, but statistical significance was not reached.
DISCUSSION
In the present study, we have demonstrated that nitric oxide synthase in the brain is suppressed by i.c.v. administration of L-NAME, leading to an in crease in infarct size following occlusion of the MeA.
There is evidence that L-NAME crosses the blood-brain barrier (Dwyer et aI., 1991) , and there fore, in many previous studies, it has been admin istered both intravenously and by intraperitoneal in jection to inhibit nitric oxide synthase in the brain. It should be noted that with systemic administration there is a possibility that some of the N OS inhibitor will be trapped in the liver (Stark and Szurszewski, 1992) as well as other systemic tissues, making it important to measure the degree of NOS inhibition directly. Systemic administration of L-NAME, however, induces marked increases in blood pres sure (Rees et aI., 1990) , which can significantly alter the course of an ischemic insult and influence the degree of infarction. L-NAME (as well as many other NOS inhibitors such as NJ -nitro-L-arginine and NJ -monomethyl-L-arginine) is strongly vasoac tive and can produce significant constriction of the resistance vessels in the brain (Prado et aI., 1992) . When L-NAME is applied intracerebroventricu larly, it diffuses from the cerebrospinal fluid to the brain tissue, perivascular nerve fibers, cerebral vas cular smooth muscle cells, glia, and neurons but does not produce changes in systemic blood pres sure. For these reasons, we have used the intra cerebroventricular route for L-NAME administra tion. The doses of L-NAME used were calculated based on the assumption that the intracerebroven tricular administered L-NAME did not distribute in a volume greater than that of the brain. These doses appear to be adequate for sllppression of NOS based on the direct measurements of catalytic ac tivity, especially in the deep structures (Fig. 2) .
We have demonstrated that the constitutive NOS catalytic activity of the rat brain was effectively suppressed by i.c. v. ad m inistration of L-NAME, but with differences among brain regions, doses, and duration after injection. The suppression of NOS was more marked in the left hemisphere than the right, with NOS inhibition more marked in re gions closer to the point of the i.c.v. injection. The i.c.v. administration of high-dose L-NAME pro duced an increase in the infarct area and volume, especially in the region anterior to the ischemic core, suggesting that NOS inhibitors can potentiate the tissue damage resulting from focal ischemia when administered i. c. v. This increase in damage can occur in spite of no direct NOS inhibition in the ischemic tissue.
NOS inhibitors have been utilized in both in vitro and in vivo studies to examine the role of NO in ischemia and neurotoxic cell damage. In cortical cell cultures, NNA and NW-monomethyl-L-arginine antagonize the NMDA receptor-mediated neuro toxicity of glutamate (Dawson et aI. , 1991) . N ow icki et al. (1991) demonstrated, in a MCA occlusion model in mice, that 1 mg/kg of �-nitro-L-arginine administered intraperitoneally in repeated doses following occlusion reduced the volume of infarc tion by 72%. A similar protective effect in focal ischemia has been measured in the rat with NNA (Nagafuji et aI. , 1992) and L-NAME (Ashwal et aI. , 1993; Buisson et aI. , 1992) and in the cat (Nishikawa et aI. , 1993) with L-NAME. Low-dose treatment with the NOS inhibitor, L-NAME, appears to be the most effective in reducing infarct volume (Ashwal et aI. , 1993; Buisson et aI. , 1993) . In contrast, some studies have shown that treatment with NOS inhib itors has no effect on ischemic damage in either focal ischemia (Dawson et aI. , 1992a) or global isch emia (Moncada et aI. , 1992) . There are also reports of adverse effects of NOS inhibition on ischemic tissue in focal ischemia models in both normoten sive (Kuluz et aI. , 1993; Zhang and Iadecola, 1993) and spontaneous hypertensive (Yamamoto et aI. , 1992) rats. Further evidence for the beneficial effect of NO following ischemia comes from data showing that the administration of NO donors such as so dium nitroprusside appear to reduce the infarct vol ume (Zhang and Iadecola, 1993) and that infusion of L-arginine, the substrate of NO synthesis, de creases the infarct size during MCA occlusion stud ies in spontaneous hypertensive rats (Morikawa et aI. , 1992a) . These reports, along with our data, sug gest that treatment with relatively high doses of NOS inhibitors may enlarge the infarct volume, while more moderate inhibition may be neuropro tective. This is consistent with the recent observa tions of Carreau et al. (1994) , in which moderate inhibition of NOS (0.1-1.0 mg/kg, administered five times postocclusion) was shown to be neuroprotec-J Cereb Blood Flow Metab. Vol. /5. No.5. /995 tive, whereas extensive inhibition of NOS (3-10 mg/ kg) exacerbated focal ischemia, due, most likely, to alterations in cerebral blood flow.
There is evidence that NO inhibition can induce a significant reduction in focal cerebral blood flow (Tanaka et aI. , 1991; Kovach et aI. , 1992) . NOS inhibition produces vasoconstriction and can in duce subtle cerebral vascular pathological changes consistent with focal ischemia (Prado et aI. , 1992) . Cerebral arteries are richly innervated by nonadren ergic noncholinergic vasodilator nerves that contain NOS (Nozaki et aI. , 1993; Suzuki et aI. , 1993) . These fibers are believed to produce NO indepen dent of the endothelium and to act directly on vas cular smooth muscle to induce vasodilation. The L-NAME infused into the cerebroventricular sys tem may act directly on the pial arteries, leading to an inhibition of NO production and a subsequent vasoconstriction. In addition, L-NAME blocks ace tylcholine-induced vasodilation, as it is a competi tive antagonist of muscarinic membrane receptors in the vascular endothelium (Buxton et aI. , 1993) . NOS inhibition impairs cerebral autoregulation (Tanaka et aI. , 1993) , which can further compro mise blood flow in the ischemic penumbra leading to an enlargement of the infarct area.
In the present study, the NOS catalytic activity in the deep gray matter, which includes the hypothal amus and basal forebrain, was markedly sup pressed, along with the NOS activity in the left (contralateral to the ischemia) cortex. NOS activity in the ischemic cortex, however, was not signifi cantly decreased. One potential mechanism by which remote NOS inhibition can effect ischemic volume is by compromising collateral blood flow. Inhibition of NOS leads to a decrease in cerebral blood flow in these nonischemic regions (Tanaka et aI. , 1991) . This decrease in blood flow can ad versely affect the collateralization of the ischemic territory, which must originate in these regions, with a resulting increase in ischemic damage (Chen et aI. , 1986) . Since release of vasopressin, which is a vasodilator, is centrally stimulated by NO (Ota et aI. , 1993) , NOS inhibition can further compromise cerebral vascular tone. Raszkiewicz et al. (1992) re-ported that NO has a role in mediating basal fore brain regulation of cortical blood flow. These data all suggest that NOS inhibition of the deep gray matter will impair control of cerebral vascular tone which may potentially lead to an enlargement of the infarction. There are also anatomical and functional connections between the cerebral cortex and the deep gray matter (Kelly and Moore, 1978; Edvins son et aI., 1993) , raising the possibility that suppres sion of NOS in neurons of subcortical gray matter may lead to modification of cortical ischemic dam age.
The i.c.v. administration of L-NAME caused an enlargement of the ischemic lesion produced by oc clusion of MCA in the rat. The apparent discrep ancy between the data in the literature, both in vitro and in vivo, and the many potential actions of nitric oxide indicates that the role of nitric oxide in cere bral ischemia is rather complex. NO clearly has both neuroprotective and neurotoxic actions in brain tissue, with the balance of these actions de termining the effect of inhibition of NOS under pathological conditions. Since NO is a strong cere bral vasodilator even in the penumbral area of the ischemic territory, and has an inhibitory effect on platelet aggregation and adhesion, NO can facilitate collateral flow and improve microcirculation in the penumbral area. On the other hand, NO mediates neurotoxicity, and inhibiting NO synthesis should reduce neuronal damage. The present study indi cates the impor�ance of examining the role of NO in cerebral ischemia. There is currently discussion of the potential therapeutic use of NOS inhibitors or donors in ischemic stroke. It is concluded from the present study that a high dose of the NOS inhibitor, L-NAME, is unlikely to be of therapeutic utility in cerebral ischemia.
